

# Anders W Erickson

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5331762/publications.pdf>

Version: 2024-02-01

10  
papers

128  
citations

1683354

5  
h-index

1588620

8  
g-index

10  
all docs

10  
docs citations

10  
times ranked

158  
citing authors

#	ARTICLE	IF	CITATIONS
1	Hazardous alcohol use and alcohol-related harm in rural and remote communities: a scoping review. <i>Lancet Public Health</i> , The, 2022, 7, e177-e187.	4.7	27
2	Stereotactic radiosurgery versus whole brain radiotherapy in patients with intracranial metastatic disease and small-cell lung cancer: a systematic review and meta-analysis. <i>Lancet Oncology</i> , The, 2022, 23, 931-939.	5.1	33
3	Necrosis and Brain Invasion Predict Radio-Resistance and Tumor Recurrence in Atypical Meningioma: A Retrospective Cohort Study. <i>Neurosurgery</i> , 2021, 88, E42-E48.	0.6	18
4	Dual- versus single-agent HER2 inhibition and incidence of intracranial metastatic disease: a systematic review and meta-analysis. <i>Npj Breast Cancer</i> , 2021, 7, 17.	2.3	2
5	Assessing the Association of Targeted Therapy and Intracranial Metastatic Disease. <i>JAMA Oncology</i> , 2021, 7, 1220.	3.4	5
6	THER-01. Targeted therapy and intracranial metastatic disease: a population-based retrospective cohort study. <i>Neuro-Oncology Advances</i> , 2021, 3, iii12-iii12.	0.4	0
7	04. ASSESSMENT OF EFFICACY AND SAFETY OF OSIMERTINIB FOR PATIENTS WITH INTRACRANIAL METASTATIC DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS. <i>Neuro-Oncology Advances</i> , 2020, 2, ii1-ii1.	0.4	0
8	Assessment of Effectiveness and Safety of Osimertinib for Patients With Intracranial Metastatic Disease. <i>JAMA Network Open</i> , 2020, 3, e201617.	2.8	28
9	HER2-targeted therapy prolongs survival in patients with HER2-positive breast cancer and intracranial metastatic disease: a systematic review and meta-analysis. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa136.	0.4	6
10	The Impact of Targeted Therapy on Intracranial Metastatic Disease Incidence and Survival. <i>Frontiers in Oncology</i> , 2019, 9, 797.	1.3	9